---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-24-000132"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:40:32.626031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4

## Summary
- Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.
- Cash $75.1M as of Sep 30, 2024 provides runway into mid-2026; R&D expenses down 38% to $8.2M.
- RLYB212 Phase 2 CTA approved by EMA and MHRA; screening for pregnant women at FNAIT risk to start Q4 2024.
- RLYB116 manufacturing improvements completed; biomarker data suggests potential in PNH and APS beyond myasthenia gravis.
- ENPP1 inhibitor candidate nomination with Exscientia on track for Dec 2024; preclinical data showed PPi reduction and improved bone mineralization.

## SEC filing metadata
- accession: 0001739410-24-000132
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000132/0001739410-24-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000132/rlyb-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-24-000132
- JSON: https://secwatch.observer/filing/0001739410-24-000132.json
- Plain text: https://secwatch.observer/filing/0001739410-24-000132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.